Last reviewed · How we verify
GCFLU Quadrivalent
At a glance
| Generic name | GCFLU Quadrivalent |
|---|---|
| Sponsor | Green Cross Corporation |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Elderly Healthy Subjects (PHASE2)
- A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults (PHASE1)
- A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age (PHASE3)
- A Study to Evaluate Efficacy and Safety of GC3110B in Healthy Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GCFLU Quadrivalent CI brief — competitive landscape report
- GCFLU Quadrivalent updates RSS · CI watch RSS
- Green Cross Corporation portfolio CI